Core Viewpoint - Changyang Technology is actively developing its CPI (Transparent Polyimide Film) project and is accelerating the development and validation process of the CPI film project [1] Group 1 - The company is currently constructing its CPI project [1] - The company aims to speed up the development and validation of the CPI film project [1]

Core Viewpoint - The company is currently constructing its first CPI film production line and is accelerating the development and validation of its CPI film products [1] Group 1 - Investors inquired about the completion status of the company's first CPI film production line [1] - The company confirmed that the CPI project is under construction [1] - The company aims to speed up the development and verification process of its transparent polyimide film products [1]

Core Viewpoint - The company is committed to strengthening its position in the functional film market by expanding its product offerings and focusing on key application areas that require import substitution [1] Group 1: Market Research and Development Plans - The company continues to conduct market research on functional films to identify potential areas for development [1] - The company aims to enhance its market position by focusing on reflective functional films and exploring new application scenarios [1] Group 2: Investment in R&D - The company is concentrating its resources and R&D team on increasing investments in optical base films, solid and semi-solid electrolyte base films, and CPI films [1] - The goal is to overcome core technological barriers and achieve industrialization while creating a champion product series [1] Group 3: Focused Application Areas - The company will prioritize four major application scenarios: new displays, semiconductors, 5G, and new energy vehicles and energy storage [1] - It plans to develop critical functional film products that are heavily reliant on imports and urgently need to achieve import substitution in these areas [1]

Core Viewpoint - The company Longyang Technology (SH688299) reported a research and development (R&D) expenditure of 48.21 million yuan for the first three quarters of 2025, indicating a commitment to innovation and development in various functional films [1] R&D Expenditure Details - The total R&D expenditure for the first three quarters of 2025 is 48.21 million yuan [1] - Specific R&D investments in various functional films such as reflective films, CPI films, semi-solid/solid battery skeleton films, semi-solid/solid battery ion-conducting films, and lithium battery separators were not detailed but can be found in the company's semi-annual and annual reports for 2025 [1]

证券代码：688299 证券简称：长阳科技 公告编号：2025-054 宁波长阳科技股份有限公司 投资者可于 2025 年 11 月 21 日 （星期五） 至 11 月 27 日 （星期四） 16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@solartrontech.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 宁波长阳科技股份有限公司（以下简称"公司"）已于 2025 年 10 月 29 日发 布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计划于 2025 年 11 月 28 日 （星期五） 14:00-15:00 举行 2025 年第三季度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2025 年第三季度的经 营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容 ...

Meeting Overview - The shareholders' meeting was held on November 14, 2025, at the company's administrative building in Wenzhou, Zhejiang [1] - The meeting was convened by the board of directors and chaired by Chairman Chen Guohua, utilizing both in-person and online voting methods [1] Attendance - All 9 current directors attended the meeting, along with all 3 current supervisors and the board secretary, Mr. Wu Chaoqun [2] Resolutions - The following resolutions were passed: 1. Proposal to abolish the supervisory board and amend the company's articles of association [3] 2. Proposal to revise certain company management systems [3] - All resolutions were approved without any dissenting votes, with the first proposal requiring a special resolution that received over two-thirds of the voting rights from attending shareholders [4] Legal Verification - The meeting was witnessed by Shanghai Lifeng Law Firm, with lawyers Liao Xueyong and Shu Yingchao confirming that the meeting's procedures complied with relevant laws and regulations [4]

Overview - Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced that its subsidiary, Shanghai Fuhong Hanlin Biotechnology Co., Ltd., received FDA approval for its self-developed biosimilar POHERDY? (HLX11) for specific indications in HER2-positive metastatic breast cancer [2][6]. Product Information - HLX11 is a biosimilar of Pertuzumab, with a specification of 420mg/14mL (30mg/mL) for intravenous injection [2]. - The approved indications include treatment in combination with Trastuzumab and Docetaxel for adult patients with HER2-positive metastatic breast cancer who have not previously received anti-HER2 treatment or chemotherapy [2]. - It is also indicated for use in early breast cancer as part of a comprehensive treatment plan for HER2-positive locally advanced, inflammatory, or early breast cancer patients [2]. Regulatory Progress - HLX11's registration progress includes: - Acceptance of the marketing authorization application by the National Medical Products Administration of China in December 2024 [3]. - Acceptance of the marketing authorization application by the European Medicines Agency in March 2025 [3]. - Acceptance of the new drug submission by Health Canada in May 2025 [3]. Financial Investment - As of October 2025, the cumulative R&D investment for HLX11 is approximately RMB 225 million (unaudited) [4]. Market Potential - According to IQVIA MIDAS data, the global sales of Pertuzumab products are projected to be approximately $3.304 billion in 2024 [5]. Strategic Impact - The approval of POHERDY? marks the fourth product approved for Fuhong Hanlin in the U.S., enhancing the company's international market presence [6]. - Commercial rights for HLX11 outside of mainland China and Hong Kong, Macau, and Taiwan were granted to Organon LLC in June 2022, allowing Fuhong Hanlin to benefit from sales milestones and royalties following the U.S. approval [6].

Core Viewpoint - Changyang Technology announced the election of Mr. Chen Zhe as the employee representative director of the fourth board of directors during the employee representative meeting held on November 13, 2025 [1] Group 1 - The employee representative meeting was convened on November 13, 2025 [1] - The agenda included the proposal for the election of the fourth board of directors' employee representative director [1] - The proposal to elect Mr. Chen Zhe was approved by the meeting [1]

证券代码：688299 证券简称：长阳科技 公告编号：2025-053 宁波长阳科技股份有限公司 2025年第四次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 （一） 股东大会召开的时间：2025 年 11 月 13 日 （二） 股东大会召开的地点：宁波市江北区庆丰路 999 号公司一楼会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 141 | | --- | --- | | 普通股股东人数 | 141 | | 2、出席会议的股东所持有的表决权数量 | 56,621,999 | | 普通股股东所持有表决权数量 | 56,621,999 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 20.0580 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 20.0580 | （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提 ...

国浩律师（上海）事务所 法律意见书 中国 上海 上海市静安区山西北路 99 号苏河湾中心 MT25-28 楼，200085 25-28/F, Suhe Centre, 99 North Shanxi Road, Jing'an District, Shanghai, China, 200085 电话/TEL: (8621) 5234-1668 传真/FAX: (8621) 5234-1670 关于宁波长阳科技股份有限公司 2025年第四次临时股东大会的法律意见书 致：宁波长阳科技股份有限公司 国浩律师（上海）事务所（以下简称"本所"）接受宁波长阳科技股份有限公 司（以下简称"公司"）委托，指派本所律师出席公司 2025 年第四次临时股东大 会（以下简称"本次股东大会"）。本所律师根据《中华人民共和国证券法》（以 下简称"《证券法》"）、《中华人民共和国公司法》（以下简称"《公司法》"）、 《上市公司股东会规则》（以下简称"《股东会规则》"）等法律、法规、部门规 章和规舃性文件以及《宁波长阳科技股份有限公司章程》（以下简称"《公司章 程》"）的规定，就公司本次股东大会的召集与召开程序、出席会议人员资格、 召集人 ...